INmune Bio Receives R&D Rebates of Approximately $4.6 Million

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million.  This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026.  After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company’s net cash used in operating activities during the quarter.  The rebates strengthen the Company’s balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™) toward regulatory filings.

Italfarmaco Announces Managed Entry Agreement in Georgia for Givinostat as Treatment for Patients with Duchenne Muscular Dystrophy

MILAN, Italy, July 31, 2026Italfarmaco S.p.A. today announced a managed entry agreement with the Georgian Ministry of Health for givinostat (Duvyzat®) as a treatment for patients with Duchenne muscular dystrophy (DMD). Based on the European Commission (EC) approval in June 2025, givinostat will be available in Georgia under this agreement for patients aged six years and over who are ambulant at the start of treatment, when taken together with corticosteroids.

Life Surge to Bring Its National Christian Live Event to Long Island as Organization Approaches 100th Main-Stage Milestone

PALMETTO, FL, July 30, 2026 (GLOBE NEWSWIRE) — Life Surge announced it will bring its nationally touring one-day Christian live event to Long Island on Saturday, August 22, at Nassau Veterans Memorial Coliseum, marking the organization’s 99th main-stage event. The event will feature nationally recognized speakers, worship, biblical teaching, leadership development, entrepreneurship, and stewardship education as Life Surge continues its expansion into new markets across the United States.